Frontotemporal dementia (FTD) encompasses a spectrum of neurodegenerative diseases with varied biological mechanisms, clinical symptoms and prognoses that come with unique challenges for clinical drug development. There are currently no approved treatments that delay or halt the progression of FTD disorders or that effectively treat symptoms. While there are increasing numbers of promising treatments entering clinical trials, the number remains small, and none have resulted in viable treatments.
The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) launched the Treat FTD Fund to provide critical funding for early-stage clinical trials that:
Deadlines for Letters of Intent: Jan. 27, 2023
Funding is open to researchers and clinicians worldwide at:
Up to $2,000,000 based on stage and scope of the trial. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and patient enrollment.
